Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved
Executive Summary
India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.
You may also be interested in...
Vision Possible: Why Eyestem Is 'Bullish' About Its Dry AMD Candidate
Eyestem founder and CEO talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.